The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Luigi Mariani
No Relationships to Disclose
 
Andrea Anichini
No Relationships to Disclose
 
Antonella Messina
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Alberto Briganti
Honoraria - Astellas Pharma; Ferring; Janssen-Cilag
Consulting or Advisory Role - Astellas Pharma; Bayer; MDxHealth; OPKO Health
Research Funding - Sandoz
 
Francesco Montorsi
No Relationships to Disclose